- Home
- JBGS vs BEAM Comparison
JBGS vs BEAM Comparison
Compare JBGS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- BEAM
- Stock Information
- Founded
- JBGS 2016
- BEAM 2017
- Country
- JBGS United States
- BEAM United States
- Employees
- JBGS N/A
- BEAM N/A
- Industry
- JBGS Real Estate Investment Trusts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JBGS Real Estate
- BEAM Health Care
- Exchange
- JBGS Nasdaq
- BEAM Nasdaq
- Market Cap
- JBGS 1.3B
- BEAM 1.6B
- IPO Year
- JBGS 2017
- BEAM 2020
- Fundamental
- Price
- JBGS $17.07
- BEAM $20.01
- Analyst Decision
- JBGS Sell
- BEAM Strong Buy
- Analyst Count
- JBGS 2
- BEAM 11
- Target Price
- JBGS $16.00
- BEAM $48.90
- AVG Volume (30 Days)
- JBGS 1.7M
- BEAM 2.0M
- Earning Date
- JBGS 07-29-2025
- BEAM 08-05-2025
- Dividend Yield
- JBGS 4.10%
- BEAM N/A
- EPS Growth
- JBGS N/A
- BEAM N/A
- EPS
- JBGS N/A
- BEAM N/A
- Revenue
- JBGS $520,825,000.00
- BEAM $63,578,000.00
- Revenue This Year
- JBGS N/A
- BEAM N/A
- Revenue Next Year
- JBGS $2.71
- BEAM $8.82
- P/E Ratio
- JBGS N/A
- BEAM N/A
- Revenue Growth
- JBGS N/A
- BEAM N/A
- 52 Week Low
- JBGS $13.28
- BEAM $13.53
- 52 Week High
- JBGS $18.86
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- JBGS 45.07
- BEAM 68.31
- Support Level
- JBGS $16.66
- BEAM $16.59
- Resistance Level
- JBGS $17.64
- BEAM $17.38
- Average True Range (ATR)
- JBGS 0.56
- BEAM 1.10
- MACD
- JBGS -0.17
- BEAM 0.35
- Stochastic Oscillator
- JBGS 16.14
- BEAM 89.70
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.